1	PHARMACOPOEIAL DISCUSSION GROUP		
3	CORRECTION		
4	CODE: Q11		
5		STERILITY: REV 1 CORR 3 Stage	5B
6	(Correction of the sign-off document signed on 30 October 2007)		
7			
8		·	
9	Items to be corrected:		
10	- Replace Aspergillus niger by Aspergillus brasiliensis throughout the text		
11			•
12	T. D.	•	•
13	European Pharma	copoeia	
14	G: t	None	Data
$\frac{15}{16}$	Signature	Name	Date 10(06/09
17	Ceste	Ceis TEL	10000
18	Japanese Pharma	copoeia	
19	a	NT	Ditt
20	Signature Hammite	Name	Date
$\frac{21}{22}$	7 7	Name For Toshiro Nakagaki	10. June, 2009
2 3	United States Pha	armaconeia "	
24			10 500 - 0
25	Signature	Name	Date Tunes 2009
26	<u> </u>		•
27	Local requirements		
28		for sterility of the product to be	examined », USP will add a
29	paragraph on « Number of a	articles to be tested ».	halla a alama (Ahin inalada
30 31		ments for testing of for pharmacy nicillins and cephalosporins; use o	
32		able 1; description of additional of	
33	membrane filtration)	able 1, description of description	
34	• USP will add requirements for medical devices in Table 2		
35	 USP will add requirements for medical devices in Table 3 		
36	· Under « Membrane Filtration », USP will add subsections / paragraphs on Prefilled		
37	Syringes, Solids for Injection other than Antibiotics, Antibiotic Solids for Injection, Antibiotic		
38	Solids, Bulks and Blends, Sterile Aerosol Products, Devices with pathways labeled sterile		
39 40	 Under « Direct Inoculation of the Culture Medium », USP will add subsections / paragraphs on Solids, Purified Cotton, Gauze, Surgical Dressings, and Related Articles, 		
40	Sterile Devices	med Comon, Gauze, Burgical Die	boings, and isolated mucles,
$\frac{41}{42}$		tions related to Catgut and other	surgical sutures for veterinary
4 3	use in Table 2.6.12 and Table 2.6.13 as well as lines 27-33 of page 6 because they are our		
44	of the scope of JP.		

